Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content

17 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/eilean-therapeutics-advances-ze74-0282-a-highly-selective-inhibitor-of-mutated-jak2-v617f-into-first-in-human-clinical-development-302645169.html

05 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/eilean-therapeutics-presents-first-in-class-malt1-degrader-te205-demonstrating-in-vivo-efficacy-in-ulcerative-colitis-at-the-4th-international-conference-on-microbiology-and-immunology-302604708.html

24 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/chemdiv-extends-discovery-and-early-development-partnership-with-mondego-bio-on-best-in-class-ptpn2-immuno-oncology-program-302593824.html

16 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/eilean-therapeutics-presents-novel-selective-brain-permeable-cdk2-inhibitor-for-treatment-of-ccne1-dependent-cancers-302586199.html

13 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/eiiean-therapeutics-presents-novel-wild-type-sparing-reversible-pan-egfr-inhibitor-ze77-0273-with-broad-activity-against-resistance-mutations-in-egfr-mutant-nsclc-at-aacr-nci-eortc-international-conference-on-molecular-targets--302582474.html

09 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/lomond-therapeutics-reports-results-from-ongoing-clinical-studies-of-lonitoclax-a-selective-bcl-2-inhibitor-with-best-in-class-selectivity-versus-bcl-xl-and-no-cyp-3a4-liability-302325763.html
ABOUT THIS PAGE